Search the Newsreel

Hamilton Wealth LLC Sells 24,338 Shares of Moderna, Inc. $MRNA

Hamilton Wealth LLC decreased its stake in Moderna, Inc. by 23.2% in the first quarter, selling 24,338 shares. Despite mixed institutional investor activity and a generally cautious analyst outlook with a "Reduce" rating, Moderna's recent quarterly results exceeded revenue and EPS expectations. Insiders have …

Amundi Reduces Holdings in Moderna, Inc. $MRNA

Amundi reduced its stake in Moderna, Inc. by 20.9% in the first quarter, selling 238,790 shares and retaining 904,823 shares valued at approximately $46 million. Despite beating reduced earnings expectations, Moderna continues to face substantial losses, declining COVID-19 vaccine demand, and a setback in …

Militia Capital Management LLC Buys New Shares in Moderna, Inc. $MRNA

Militia Capital Management LLC acquired 23,001 shares of Moderna, Inc. (NASDAQ:MRNA) worth approximately $1.168 million in the first quarter. This comes as various institutional investors have adjusted their stakes in Moderna, and company insiders have sold shares. The article also provides an overview of …

Does Moderna’s Wider 2026 Loss Amid Pipeline Spend Change The Bull Case For MRNA?

Moderna reported a wider net loss of US$2.13 billion in the first half of 2026 due to significant pipeline development spending, despite a slight revenue increase. The company's investment narrative heavily relies on FDA approval for its influenza vaccine, mFLUSIVA, and successful commercialization of …

ETFs Investing in Moderna, Inc. Stocks

This article provides a comprehensive list of ETFs that invest in Moderna, Inc. stocks, detailing market value, weight, issuer, management style, expense ratio, and AUM for each fund. It aims to help investors identify various ETF options for gaining exposure to Moderna, Inc. while …

Moderna, Inc. $MRNA Position Reduced by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Moderna (MRNA) by 29.7% in Q1 2026, selling 132,808 shares and retaining 314,872 shares valued at $16.0 million. Despite Moderna reporting a better-than-expected Q2 loss and improved revenue, the company faces declining COVID-19 vaccine sales, …

Moderna (MRNA) Stock Falls As Pipeline Delays Cloud Revenue Growth

Moderna Stock Falls 5% After Trimming Financial Outlook

Moderna Number of Employees 2026 | Employee Count & Headcount Data

Moderna (NASDAQ: MRNA) had approximately 4,670 total employees worldwide as of March 2026, representing a 16.3% decline since 2023. Despite this reduction in overall headcount, the company is actively hiring, with 219 active job postings in 2026, a 23.5% increase from 2025. The workforce …

Moderna, Inc. 2026: Revenue $145M, Net income ($782M), EPS ($1.97) — 10-Q Summary

Moderna, Inc. reported its 2026 quarterly results, showing revenue of $145 million, a net loss of $782 million, and a diluted loss per share of $1.97. The company experienced slight revenue improvement and narrower losses compared to the prior year. Revenue growth was attributed …

Moderna Says Norovirus Vaccine Didn’t Meet Statistical Criteria for Early Success in Trial

Moderna's stock fell after its norovirus vaccine candidate failed to meet early success criteria in a late-stage trial's interim analysis. The company announced it is still enrolling additional participants for the ongoing, blinded study. This news came as Moderna narrowed its second-quarter loss, with …

Moderna (Nasdaq: MRNA) details Q2 loss and $950 million patent settlement

Moderna (MRNA) reported a Q2 2026 net loss of $782 million, or $(1.97) per share, with revenue of $145 million, roughly flat year-over-year. The company's six-month net loss widened to $2.125 billion due to a significant increase in the cost of sales, primarily driven …

Moderna Inc reports results for the quarter ended June 30 - Earnings Summary

Moderna Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief announcement about these financial results. Readers can access the full report for detailed information.

Moderna maintains 10% growth target despite Phase 3 norovirus miss

Moderna is upholding its target of up to 10% revenue growth for the year, largely due to strong ex-U.S. vaccine sales and the anticipated approval of its seasonal flu vaccine, mFLUSIVA, despite a recent setback in its Phase 3 norovirus vaccine trial. The norovirus …

Moderna Q2 earnings beat estimates as norovirus vaccine stumbles

Moderna reported a narrower net loss in Q2 2026, beating Wall Street estimates, and saw a slight increase in total revenue. However, the company's stock dropped after its norovirus vaccine candidate failed to meet early success criteria in a Phase 3 trial. Moderna improved …

Moderna, Inc., (MRNA) Earnings Preview: Reports Before the Open

Moderna, Inc. (MRNA) is scheduled to report its earnings before the market opens. Investors will be focusing on the sales performance of its RSV vaccine and the data from its personalized mRNA cancer trial to gauge the company's future growth prospects beyond COVID boosters.

Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates

Moderna (MRNA) reported a Q2 loss of $1.97 per share, matching Zacks Consensus Estimate, and surpassed revenue estimates with $145 million, beating expectations by 14.49%. The company has consistently topped revenue estimates and its shares have significantly outperformed the S&P 500 year-to-date. Despite the …

Moderna Says Early Results of Norovirus Shot Were Not Successful

Moderna announced that early results from a key phase 3 trial for its norovirus vaccine did not meet statistical criteria for early success, marking a setback for the company's diversification efforts. The study is still ongoing, and Moderna plans to recruit more patients to …

Moderna: Q2 Earnings Snapshot

This article is a placeholder for Moderna's Q2 earnings snapshot. It currently contains no detailed information regarding the company's financial performance.

Moderna (NASDAQ: MRNA) Q2 2026 loss, trims 2026 spending

Moderna reported a net loss of $782 million, or $1.97 per share, for Q2 2026, despite revenue slightly exceeding the prior year at $145 million. The company reiterated its target of up to 10% revenue growth for 2026 and improved its financial outlook by …

Moderna beats quarterly revenue estimates on COVID vaccine strength

Moderna exceeded Wall Street's second-quarter revenue estimates due to strong COVID-19 vaccine sales, despite a setback with its experimental norovirus vaccine candidate. The company aims to offset declining pandemic-era vaccine sales with its flu shot and a future COVID-flu combination, reaffirming its revenue growth …

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates

Moderna reported its second-quarter 2026 financial results, with total revenue of $0.1 billion, a GAAP net loss of $(0.8) billion, and GAAP EPS of $(1.97). The company reiterated its plan for up to 10% revenue growth in 2026, improved its GAAP operating expense outlook …

Moderna's Flu Vaccine Could Become Its Fifth Approved Product

Moderna reported Q2 2026 revenue of $145 million, a slight increase from the prior year, alongside a GAAP net loss of $(782) million. The company reiterated its target of up to 10% revenue growth for 2026 and improved its year-end cash projections. A significant …

South Dakota Investment Council Trims Holdings in Moderna, Inc. $MRNA

The South Dakota Investment Council reduced its stake in Moderna (NASDAQ: MRNA) by 41.1% in the first quarter, selling 69,478 shares but retaining 99,552 shares valued at approximately $5.1 million. Despite this, institutional ownership remains high at 75.33%, with other major investors increasing positions. …

Moderna, Inc. $MRNA Shares Sold by Bank of Nova Scotia

Bank of Nova Scotia significantly reduced its stake in Moderna (NASDAQ:MRNA) by 87.9% in the first quarter, selling over 56,000 shares. Despite institutional investors owning three-quarters of the company, Moderna missed quarterly earnings estimates, reporting a $3.40 loss per share, though revenue increased by …

Moderna (MRNA) Shares Drop After Q2 Earnings and Forecast Cut

Moderna Q2: Weak Revenue, Strong Pipeline - Here's What Matters Now (NASDAQ:MRNA)

MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback

Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision

Baillie Gifford Reduces Moderna Inc (MRNA) Stake -- Shares Trade at 2.54x GF Value

Baillie Gifford reduced its stake in Moderna Inc (MRNA) by selling 1,779,098 shares at $70.03 each, decreasing its holdings by 8.90%. This transaction reflects Baillie Gifford's long-term investment philosophy focused on sustainable growth, even as Moderna's stock is deemed "Significantly Overvalued" by GuruFocus. Despite …

From biotech to fusion, CFS' new CFO has a plan to tap long-term capital

Commonwealth Fusion Systems (CFS) new CFO, Lorence Kim, formerly of Moderna, emphasizes the critical role of long-term capital access for financing fusion energy development. Kim believes the financial lessons learned from Moderna's capital-intensive biotech journey can be applied to CFS, which faces significant capital …

MRNA Looks 152.3% Overvalued on GF Value™

Moderna Inc (MRNA) is highlighted as 152.3% overvalued according to GuruFocus' GF Value™ metric, trading at $57.49 against an intrinsic value of $22.79 per share. The company is set to release Q2 2026 earnings, with analysts forecasting a loss per share and revenue decline, …

Moderna Q2 preview - cash burn, vaccine sales on focus (MRNA:NASDAQ)

Moderna (MRNA) is set to release its Q2 earnings on Friday, with expectations of a $2 per share loss and a 28% decline in revenue to $103M. The company, known for its COVID-19 vaccine, has been focusing on cost reduction strategies. Investors will be …

Hamilton Wealth LLC Buys 137,118 Shares of Moderna, Inc. $MRNA

Hamilton Wealth LLC significantly increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 130.5% in the first quarter, acquiring an additional 137,118 shares, bringing its total to 242,184 shares valued at over $12.3 million. This comes as other hedge funds also adjusted their positions in …

Moderna Inc (MRNA) suffers a 12.5% weekly break as momentum weakens

The biotechnology stock’s latest weekly close leaves the one-month move under pressure, even as the longer 12-week return remains positive.

Moderna (MRNA) Q2 Earnings: What To Expect

Moderna (MRNA) is set to announce its Q2 earnings this Friday. The market anticipates a 24.8% year-on-year revenue decline, an improvement from the previous year's 41.1% decrease. Despite positive sentiment in the biotechnology sector, Moderna's stock is down, and its current share price exceeds …